Prof. Mohssen Elalfy

Ain Shams University, Egypt

Email: [email protected]

Qualifications

1986 Ph.D., Ain Shams University

1982 M.Sc., Ain Shams University

1978 B.Sc., Ain Shams University

Publications (selected)

1. Hassan, T., Elalfy, M., Youssef, M. A. M., et al. (2026). Multicentre Retrospective and Prospective Analysis of Data on Emicizumab and Factor VIII Prophylaxis in Children With Severe Haemophilia A: Egypt-Compare Study. Haemophilia.
2. Elalfy, M., Mehanna, N., Ghazala, H., et al. (2025). Gut microbiota pattern in children and adolescents with newly diagnosed immune thrombocytopenia. BMC Pediatrics, 25(1), Article 538.
3. Elalfy, M. S., Hamdy, M., & Adly, A. (2025). Efficacy and Safety of Early-Start Deferiprone in Infants and Young Children With Transfusion-Dependent Beta Thalassemia: Evidence for Iron Shuttling to Transferrin in a Randomized, Double-Blind, Placebo-Controlled, Clinical Trial (START) (vol 100, pg 1415, 2023). American Journal of Hematology, 100(8), 1472–1473.
4. ElAlfy, M. S., Ismail, E. A. R., Makkeyah, S. Mostafa., et al. (2025). Vasculopathy among children and adolescents with sickle cell disease: the crosstalk with annexin A1, vitamin D, and myocardial iron overload. Expert Review of Hematology, 18(6), 481–490.
5. Miri, S., Rosendaal, F. R., Kavakli, K., et al. (2024). Inhibitor development upon switching from plasma-derived to recombinant factor VIII in previously untreated patients with severe hemophilia A: the PUP-SWITCH study. Research and Practice in Thrombosis and Haemostasis, 8(8), Article e102595.
6. Hassan, S., Baselli, G., Mollica, L., et al. (2024). Predicting inhibitor development using a random peptide phage-display library approach in the SIPPET cohort. Blood Advances, 8(11), 2880–2889.
7. Hassan, T., Lotfy, G., Elalfy, O., et al. (2024). Multicenter retrospective and prospective analysis of emicizumab and FVIII prophylaxis in children with severe hemophilia A. Haemophilia, 30(Suppl 2), 222–223.
8. Hamdy, M., El-Beshlawy, A., Verissimo, M. P. A., et al. (2024). Deferiprone versus deferoxamine for transfusional iron overload in sickle cell disease and other anemias: Pediatric subgroup analysis of the randomized, open-label FIRST study. Pediatric Blood & Cancer, 71(1), Article e30711.
9. Schifferli, A., Moulis, G., Godeau, B., et al. (2023). Adolescents and young adults with newly diagnosed primary immune thrombocytopenia. Haematologica, 108(10), 2783–2793.
10. Elalfy, M. S., Ramadan, S., Kamel, S. N., et al. (2023). Iron Status and Overload in Children With Acute Lymphoblastic Leukemia (ALL) during Different Phases of Therapy in a Pediatric Oncology Center in Egypt. Clinical Lymphoma Myeloma & Leukemia, 23(Suppl 1), S236–S236.
11. Elalfy, O., Elalfy, M., Adly, A., et al. (2023). Localized and Generalized Lymphadenopathy Referred to 3 Tertiary Pediatric Centers Over 6 Years: The Alarming Signs. Clinical Lymphoma Myeloma & Leukemia, 23(Suppl 1), S236–S237.
12. Aly, N. H., Elalfy, M. S., Elhabashy, S. A., et al. (2023). A stepwise diagnostic approach for undiagnosed Anemia in children: A model for low-middle income country. Blood Cells Molecules and Diseases, 103, Article 102779.
13. Elalfy, M. S., Hamdy, M., Adly, A., et al. (2023). Efficacy and safety of early-start deferiprone in infants and young children with transfusion-dependent beta thalassemia: Evidence for iron shuttling to transferrin in a randomized, double-blind, placebo-controlled, clinical trial (START). American Journal of Hematology, 98(9), 1415–1424.
14. Elalfy, M. S., Hamdy, M., El-Beshlawy, A., et al. (2023). Deferiprone for transfusional iron overload in sickle cell disease and other anemias: open-label study of up to 3 years. Blood Advances, 7(4), 611–619.
15. Elalfy, M., Eltonbary, K., Elalfy, O., et al. (2023). SURVEY AND UPDATE ON THE PRACTICE OF IMMUNE TOLERANCE INDUCTION IN PATIENTS WITH HAEMOPHILIA A AND FACTOR VIII INHIBITORS ACROSS EAST MEDITERRANEAN REGION. Haemophilia, 29(Suppl 1), 69–69.
16. Elalfy, M., Adolf, S., & Elekiaby, M. (2023). TOWARDS AN EGYPTIAN NATIONAL CONSENSUS ON MANAGEMENT OF INHIBITORS AGAINST CLOTTING FACTOR CONCENTRATES, A CHANGING PARADIGM. Haemophilia, 29(Suppl 1), 69–70.
17. Elalfy, M., Elalfy, O., & Adly, A. (2022). Splenomegaly Is an Alarming Sign of Non-Benign Lymphadenopathy in Children Referred to a Tertiary Center. Clinical Lymphoma Myeloma & Leukemia, 22(Suppl 2), S203–S204.
18. Makkeyah, S., Elsayed, M. S., Ragab, I., & Elalfy, M. (2022). Outcome of Acute Leukemia in Down Syndrome: A Retrospective Experience of Ain Shams Pediatric Oncology Over a Decade. Clinical Lymphoma Myeloma & Leukemia, 22(Suppl 2), S194–S195.
19. Mosaad, B. M. R., Ibrahim, A. S., Mansour, M. G., et al. (2022). The role of MRI-R2*in the detection of subclinical pancreatic iron loading among transfusion-dependent sickle cell disease patients and correlation with hepatic and cardiac iron loading. Insights into Imaging, 13(1), Article 140.
20. Rakha, M., Adolf, S., Sobhy, G., et al. (2022). Von Willebrand Disease (VWD) incidence among patients with bleeding manifestations in Egypt-A study cohort from VWD Registry. Haemophilia, 28(Suppl 3), 91–91.

Profile Details
https://www.researchgate.net/profile/Mohsen-Elalfy
https://scholar.google.com/citations?user=cYsqmM0AAAAJ&hl=en

WOS ResearcherID: DXE-8456-2022